ReviewCells2023
Potential Therapeutic Use of Stem Cells for Prion Diseases.
Review in Cells, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- The SLC7A11 Thermostat: A Molecular Signaling Switch Between Ferroptosis and Disulfidptosis in Neurodegenerative Disease.Molecular neurobiology · 2026Review
- Integrating Single-Cell Sequencing and Proteomics to Unravel Stem Cell Heterogeneity: Implications for Precision Regenerative Medicine.Stem cell reviews and reports · 2026Review
- Stem Cell Therapy: Past, Present, and Future Aspects.Biomedicines · 2026Review
- Ferroptosis-related mechanisms in prion diseases provide insights into neurodegeneration and reveal therapeutic implications.Redox biology · 2026Article
- Transcriptomic and functional comparison of adipose-and bone marrow-derived mesenchymal stem cells for tendon regeneration.Stem cell research & therapy · 2026Article
- Mesenchymal stem cell-derived exosomes as a potential therapeutic strategy for ferroptosis.Stem cell research & therapy · 2025Review
- Mesenchymal Stem Cell Secretome Attenuates PrPCells · 2025Article
- Therapeutic effects of adipose-derived mesenchymal stem cells combined with glymphatic system activation in prion disease.Molecular neurodegeneration · 2025Article
- Biological characteristics and transcriptomic profile of adipose-derived mesenchymal stem cells isolated from prion-infected murine model.Stem cell research & therapy · 2025Article
- Enhanced tenogenic potential of tendon-derived mesenchymal stem cells: transcriptomic profiling andFrontiers in cell and developmental biology · 2025Article
- Novel Insertion/Deletion Polymorphisms and Genetic Studies of the Shadow of Prion Protein (Animals : an open access journal from MDPI · 2024Article
- A Systematic Review of Sporadic Creutzfeldt-Jakob Disease: Pathogenesis, Diagnosis, and Therapeutic Attempts.Neurology international · 2024Review
- Novel Single-Nucleotide Polymorphisms (SNPs) and Genetic Studies of the Shadow of Prion Protein (Animals : an open access journal from MDPI · 2024Article
- Assessment of the therapeutic potential of Hsp70 activator against prion diseases usingFrontiers in cell and developmental biology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Prion diseases are neurodegenerative disorders that are progressive, incurable, and deadly. The prion consists of PrP
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.